Elanco Animal Health (NYSE:ELAN) Given New $19.00 Price Target at Barclays

Elanco Animal Health (NYSE:ELAN) had its price target reduced by Barclays from $22.00 to $19.00 in a research note released on Monday, Benzinga reports. They currently have an overweight rating on the stock.

A number of other research analysts have also recently issued reports on the stock. Morgan Stanley cut shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Piper Sandler decreased their price objective on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a report on Monday, July 1st. Finally, Stifel Nicolaus restated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and an average price target of $17.00.

Elanco Animal Health Stock Up 2.1 %

Shares of NYSE:ELAN opened at $12.77 on Monday. Elanco Animal Health has a one year low of $8.59 and a one year high of $18.80. The company has a 50 day moving average of $14.19 and a 200-day moving average of $14.75. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. The stock has a market cap of $6.31 billion, a price-to-earnings ratio of -4.82, a P/E/G ratio of 1.32 and a beta of 1.40.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The firm had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.18 earnings per share. On average, sell-side analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insider Activity

In related news, Director Michael J. Harrington purchased 3,500 shares of Elanco Animal Health stock in a transaction dated Thursday, August 22nd. The stock was bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the acquisition, the director now directly owns 81,094 shares of the company’s stock, valued at $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 100,000 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were acquired at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. This trade represents a 200.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Harrington acquired 3,500 shares of the business’s stock in a transaction dated Thursday, August 22nd. The stock was acquired at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the transaction, the director now owns 81,094 shares of the company’s stock, valued at $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.57% of the company’s stock.

Institutional Trading of Elanco Animal Health

Institutional investors have recently made changes to their positions in the business. ASB Consultores LLC raised its position in Elanco Animal Health by 33.9% during the third quarter. ASB Consultores LLC now owns 23,700 shares of the company’s stock worth $348,000 after acquiring an additional 6,000 shares in the last quarter. Innealta Capital LLC raised its position in Elanco Animal Health by 78.1% during the third quarter. Innealta Capital LLC now owns 19,981 shares of the company’s stock worth $294,000 after acquiring an additional 8,760 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in Elanco Animal Health by 101.1% during the third quarter. Harbor Capital Advisors Inc. now owns 874,895 shares of the company’s stock worth $12,852,000 after acquiring an additional 439,757 shares in the last quarter. Private Management Group Inc. raised its position in Elanco Animal Health by 62.6% during the third quarter. Private Management Group Inc. now owns 1,442,334 shares of the company’s stock worth $21,188,000 after acquiring an additional 555,131 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after acquiring an additional 2,044 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.